Free worldwide shipping on orders over $150
Two cheaper paths to semaglutide outside brand-name Wegovy or Ozempic: compounded semaglutide from US compounding pharmacies, and Indian generic semaglutide from licensed manufacturers like Sun Pharma and Alkem. They are not the same product. This guide explains the differences in regulation, sourcing, dosing predictability, and risk.
During the official Wegovy/Ozempic shortage (declared by the FDA in 2022), US-based 503A and 503B compounding pharmacies were permitted to compound semaglutide using bulk active pharmaceutical ingredient (API). The compounded products are not FDA-approved, often contain "semaglutide salts" rather than the original molecule, and the FDA has issued multiple safety warnings about dosing errors, contamination, and adverse events. The shortage was declared resolved in 2025, and the FDA has signaled that compounding for non-shortage reasons is no longer permissible.
Indian generic manufacturers — Sun Pharma (Noveltreat), Alkem (Semasize), Torrent Pharma (Sembolic) — produce semaglutide as a finished pharmaceutical product under WHO-GMP standards, licensed by CDSCO. The molecule is the same semaglutide as Wegovy/Ozempic/Rybelsus, in the same pen or tablet format, at the same titration doses. The difference from compounded products: it is a complete finished medication, manufactured by a licensed pharmaceutical company, not assembled from bulk API by a compounding pharmacy.
LiberaCure routes to licensed Indian manufacturers because the regulatory and dosing predictability is materially better. A pre-filled Sun Pharma pen at a labeled dose is a finished pharmaceutical product. A vial of "semaglutide sodium" reconstituted at home is an open-loop system where the user becomes the QA layer. Both are cheaper than brand Wegovy. Only one is a complete pharmaceutical product.
Semaglutide is not a controlled substance. The US FDA permits personal importation of unapproved foreign medications under enforcement discretion, typically interpreted as a 90-day supply. Other Western jurisdictions have similar frameworks. Specific GLP-1 import rules can change rapidly during shortage / re-supply periods — the Australian TGA is a notable example of jurisdiction-specific tightening. Verify your country's current stance.
Pharmacologically yes — same molecule, same titration doses, same pen format. It is manufactured by licensed Indian pharmaceutical companies (Sun Pharma, Alkem, Torrent Pharma) under WHO-GMP standards. The difference from brand Wegovy is country of manufacture, brand label, and price — not the active drug.
It's not categorically bad — many users have used it without incident — but it carries materially higher dosing-error risk (reconstitution math, draw-up math) and the FDA has issued multiple safety warnings about adverse events. Now that the shortage is resolved, the FDA has signaled compounding for non-shortage reasons is no longer permissible. We prefer routing to a finished pharmaceutical product.
Both are dramatically cheaper than brand Wegovy (~$1,300/month US retail). Compounded semaglutide ran roughly $200–$400/month during the shortage. Indian generic Wegovy-equivalent pens (Noveltreat, Semasize) typically run $80–$200/month at standard maintenance doses.
In thermal-protection packaging via India Post International or DHL Express. Transit ~2 weeks. Refrigerate immediately on arrival. After first use, the pen can be kept at room temperature (≤30°C / 86°F) for up to 6 weeks per the manufacturer's instructions.
LiberaCure Editorial Team· Last updated April 24, 2026
Medical disclaimer: LiberaCure is a routing front-end for licensed Indian generic pharmacies. We are not pharmacists, doctors, or licensed dispensers. Information on this page is educational only and is not a substitute for professional medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before starting, changing, or stopping any medication.